A Phase I/II Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DurvaRad
- 05 Feb 2019 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 05 Feb 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated